Cardinal Health, Inc. vs NEC Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and NEC Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating NEC Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and NEC Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$24B for NEC Corporation, while their respective market capitalizations stand at $56.0B and $40.2B. Cardinal Health, Inc. is headquartered in United States and NEC Corporation in Japan, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

NEC Corporation: NEC Corporation is a Tokyo-based technology company with 101,800 employees and FY26/3 revenue of ~$24 billion (3,582.7 billion yen). It no longer makes consumer PCs or phones; instead it builds and runs IT systems for Japanese government and business, supplies telecom network gear and submarine cables, makes radar, satellite and defense communications systems, and sells biometric identification used at airports and borders. It is listed on the Tokyo Stock Exchange Prime Market under ticker 6701.

Cardinal Health, Inc. and NEC Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and NEC Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

NEC Corporation business model: NEC makes money by selling technology projects and recurring services to governments, enterprises and telecom carriers. In FY26/3 (year ended March 31, 2026), IT Services produced ~$16.8 billion (2,508.9 billion yen), about 70% of revenue: system integration, managed services and the BluStellar DX offering in Japan, plus digital government and digital finance software abroad through subsidiaries such as Avaloq, KMD and NEC Software Solutions UK. Social Infrastructure added ~$6.27 billion (935.3 billion yen), about 26%, from telecom network equipment and software, submarine cable systems, and aerospace and national security systems. Biometric identification (NeoFace face recognition, fingerprint and iris matching) is sold across both segments to airports, border agencies and police.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of NEC Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

NEC Corporation competitive advantage: NEC's edge comes from decades of trusted delivery to Japanese ministries, municipalities, the Ministry of Defense and NTT-group carriers, which makes it hard to displace on security-sensitive systems. Its face and fingerprint algorithms have repeatedly placed at or near the top of US NIST benchmark tests, which supports border-control and airport contracts abroad. It is also one of only a handful of companies (with SubCom and Alcatel Submarine Networks) able to build and lay transoceanic submarine cable systems.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and NEC Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

NEC Corporation growth strategy: Under its 2025 Mid-term Management Plan, which NEC says it achieved in FY26/3, the company prioritized digital government and digital finance, 5G, and core DX (now branded BluStellar) as growth businesses while monitoring and pruning low-profit work. Current priorities include BluStellar consulting-led modernization in Japan, AI services including its cotomi language model and partnerships with US AI firms, defense and space systems, and international digital government software.

A closer look at the financial trajectory of Cardinal Health, Inc. and NEC Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

NEC Corporation: NEC's numbers show a company trading revenue for margin. Revenue moved from ~$20.2 billion (3,014.1 billion yen) in FY22/3 to ~$24 billion (3,582.7 billion yen) in FY26/3, but the bigger change was profitability: FY26/3 adjusted operating profit reached ~$2.59 billion (386.8 billion yen) (10.8% margin, up 2.4 points), net profit attributable to owners was ~$1.81 billion (270.2 billion yen), and non-GAAP net profit was ~$1.87 billion (279.8 billion yen), a record under IFRS. Momentum carried into FY27/3: first-quarter revenue rose 14.5% to ~$5.49 billion (819.8 billion yen), net profit was ~$333 million (49.7 billion yen), and NEC raised full-year guidance to ~$23.7 billion (3,540 billion yen) revenue and ~$2.88 billion (430 billion yen) adjusted operating profit.